The Pig Veterinary Society's revised 2009 edition of Casualty Pig, funded by the BVA Animal Welfare Foundation (BVA AWF) is now available.
This booklet is intended for the use of stock keepers on farms, staff in abattoirs, veterinary surgeons, and by transporters, to give guidance and knowledge in care, treatment, and euthanasia of the casualty pig. It also indicates the responsibilities and decisions related to the "Casualty Pig", as well as the legal requirements.
Speaking on behalf of the charity, BVA AWF Chairman and veterinary surgeon, Carl Padgett, said "This updated version has more emphasis on the care of and welfare of the casualty pig than earlier editions. This is a useful and easy to use guide that gives details of 'decision options' with a series of examples related to care, treatment and euthanasia."
Individuals can obtain copies of The Casualty Pig by contacting BVA AWF trustee David Chennells, via email at acornhousevets@btconnect.com.
Grahame Gardner has introduced the M559, a classically styled tunic, stocked for the first time in bottle green.
The company says that although it has sold numerous ladies tunics in bottle green, this is the first time it has stocked a male tunic in the characteristic veterinary colour.
The M559 incorporates side fastening with the option of contrasting epaulettes, alongside practical pockets and side slits.
Simon Ward, Sales Director said: "We are delighted to introduce this new garment to the veterinary market. We are continually reviewing our range in response to customer comments, and felt it was time we stocked a bottle green option, specifically for male members of the veterinary team."
Stocked in sizes from 34" to 50" (chest), the M559 is just one of several new styles introduced in Grahame Gardner's latest brochure. The company is also launching a new men's scrub tunic. The SS3295 has a v style neck, complemented by the v-detail on the sleeves, and contrasting trim available on the neck, sleeve and pocket. Also stocked in bottle green, the company says this tunic is aimed at veterinary professionals who prefer a more relaxed approach to uniforms.
To explore Grahame Gardner's collection please take a look at http://www.grahamegardner.co.uk/, or call 0116 255 6326 to order a copy of their new brochure.
Norbrook Laboratories has announced the addition of new indications to its Loxicom (meloxicam) products, two regarding its use in cats, and the other in calves.
Loxicom 5mg/ml solution for injection for dogs and cats is now indicated for the management of post-operative pain in cats. An injection given around the time of surgery can be followed up with a course of Loxicom 0.5 mg/ml oral suspension for cats. Alternatively, for cats where no follow-up oral treatment is possible, for example with feral cats, a larger dose of the injectable formulation can be given at the time of surgery.
Norbrook's EU Veterinary Advisor, Rebekah Dudek MRCVS, said: "Norbrook is pleased to be able to now offer vets two on-licence choices in relation to how they want to use their 5mg/ml meloxicam injection in cats. This gives vets the flexibility they need to be able to deal effectively with the wide variety of cases they see every day."
Loxicom 20mg/ml solution for injection for cattle, pigs and horses has now been licenced for the relief of post-operative pain following dehorning in calves.
Norbrook says that the use of a non-steroidal antiinflammatory drug (NSAID) alongside local anaesthetic has clear benefits for animal welfare, and that use at this time is also shown to offer economic benefits to the farmer, with increased food-conversion efficiency compared to untreated calves1.
Rebekah said: "Dehorning in calves has long been known as a painful procedure, with a negative impact on feed intake in the post-operative period. With our latest licence, Loxicom 20mg/ml can now be used for relief of this potentially economically important post-operative pain in calves."
Reference
CEVA Animal Health has launched Marbokem, a Marbofloxacin-based antimicrobial for the treatment of respiratory disease in cattle which offers the advantages of a one-shot protocol and a shock-resistant vial.
Marbokem is used for the treatment of respiratory infections caused by sensitive strains of Pasteurella multocida, Mannheimia haemolytica and Histophilus somni. CEVA says Marbofloxacin's efficacy has been proven in terms of re-treatment rate, success, speed of action and MICs in comparison with many frequently used quinolones and macrolides. (1,2,3,4)
According to CEVA, Marbokem's one shot protocol means it's quick and economical to use, while its presentation in an ergonomic CLAS vial makes for light and shock-resistant handling, resulting in fewer breakages and reduced costs. The company says Marbokem is also very competitively priced.
For further product information, please contact CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
1 Grandemange, E., Fournel, S., Woerhle, F. (2009) Field evaluation of the efficacy of 2 antibiotics in treating bovine respiratory infections. Poster, Journées Nationales des GTV, Nantes, France. 2. Grobbel, M., Lübke-Becker, A., Wieler, L., Froyman R., Friederichs, S., Filios, S. (2007) Comparative quantification of the in-vitro activity of veterinary fluoroquinolones. Veterinary microbiology 124 (73-81). 3. Roy, O., Pillet, F., Heurtin-Vallé, A., Frontczak, N. (2008) Comparative field clinical efficacy of a single intramuscular injection of marbofloxacin in the treatment of bovine respiratory disease. Poster, World Buiatrics Congress, Budapest, Hungary.4. Wu, C. (2004) Determination of minimum inhibitory concentrations of danofloxacin and other commonly used cattle antimicrobial agents against Mycoplasma bovis isolated from cattle with clinical disease. Le médecin vétérinaire du Québec. 34 (1-2).
Velactis (cabergoline) is a POM marketed by Ceva Animal Health, used in the herd management programme of dairy cows as an aid in abrupt drying-off, by reducing milk production.
The product was authorised through the European Medicines Agency (EMA) in December 2015 and was first sold in the UK in April 2016.
The VMD says it has been made aware of reports of serious adverse events, predominantly occurring in Denmark, involving recumbency (lying down and unable to rise) and some deaths. Most adverse events occurred within 8 to 24 hours following product administration. Anecdotal evidence suggests that hypocalcaemia treatments may be successful in reversing clinical signs.
Ceva has decided to stop further distribution of the product in Europe voluntarily, pending the outcome of further investigations to assess a possible causal link between the product and the adverse events reported.
The VMD, EMA, other agencies throughout Europe and the MAH are working closely to monitor the situation.
The VMD highlights that due to the nature and use of the product there is no risk to human health or consumer safety.
Vets and dairy farmers are strongly encouraged to report any adverse events associated with use of Velactis to the VMD using its online reporting form or directly to Ceva for further investigation by the MAH as necessary.
Described as a first-of-its-kind, mobile-enabled digital whitepaper, the publication offers veterinary surgeons and farmers a resource on ketosis, scientific insights on the impact of the disease, and tools to help optimize dairy herd management.
According to the company, the whitepaper reveals that ketone bodies play a more significant role in metabolic diseases than was previously realized, and that beta-hydroxybutyrate is a good indicator of the presence of subclinical ketosis in dairy cattle.
Rinse Boersma, Dairy Species Manager, Animal Health, Bayer said: "Recognizing the significance of ketone bodies is a positive step towards further enhancing dairy cattle health and welfare. Veterinarians can now reliably detect the presence of subclinical ketosis in dairy herds with a simple blood test, and act quickly with the appropriate corrective measures to arrest disease progression."
Also at Congress, Bayer revealed its enhanced BCS Cowdition smartphone application, designed to support ease and accuracy of body condition scoring (BCS) of dairy cows. Bayer says the upgrade helps farmers to improve herd health management by enabling assessment of individual cows’ BCS scores based on its lactation cycle, alerts for cows that need to be attended to, and a dashboard that offers farmers an overview of their entire herd’s health.
BCS Cowdition is available in 10 languages and is free for download from the AppStore and GooglePlay.
The study, published in Nature Scientific Reports, investigated the effect of culling in the first three licensed badger cull areas – Gloucestershire, Somerset and Dorset – using data from 2013 to 2017.
Gloucestershire and Somerset saw reductions in bTB incidence rates in cull areas relative to comparison areas of 66 per cent and 37 per cent respectively after four years. In Dorset, there was no change in incidence rates in cull areas relative to comparison areas after two years, but incidence dropped by 55 per cent in the same period in the 2km buffer zone around the edge of the cull area. Matched comparison areas were similar but not identical.
James Russell, BVA Junior Vice President said: "These findings are encouraging and offer further evidence that badger culling can result in significant reductions in the number of new cases of TB in cattle. However, they come with the caveat that the data only relates to the first three cull areas, and the variability within these alone makes it too early to draw firm conclusions that culling will reduce incidence significantly in all 40 areas where it is now taking place.
"BVA’s expert working group is currently considering all aspects of disease control looking at cattle testing, removal of reactors, compensation and control in other farmed animals as well as the culling and vaccination of badgers. The group will consider this additional evidence as we develop our new policy on bTB.
"We continue to support a comprehensive and evidence-based approach to tackling bTB, including the use of badger culling where there is a demonstrated need and where it is done safely, humanely and effectively as part of a comprehensive strategy.
"The best way of halting the spread of this devastating disease is enhancing our understanding of bTB and applying that evidence to the eradication process.”
1243 farmers took part in the survey, which was held in partnership with the National Beef Association, British Dairying magazine, the relevant farming unions and the four eradication programmes.
Matt Yarnall from Boehringer said: "Reliance on veterinary input for this decision shows how valuable client discussion and guidance is. And further interrogation of the data shows other areas of BVD control where veterinary input could be extremely valuable.
"Too many producers are still holding onto PI animals in the hope they can be reared successfully and too many are making basic mistakes when it comes to herd biosecurity.
"The survey data revealed that 43% of farmers in Wales have identified a PI, but it is hugely concerning that almost half (42%) of these producers would not cull them immediately; these animals will go on to spread virus throughout the herd."
In Northern Ireland, 26 individual producers said they have kept a PI. "However, 20 had to be put down before reaching adulthood or had to be treated for other health conditions," said Matt. "Even in Scotland, with its well-established scheme, a small percentage of farmers claim they would isolate a PI and try to rear to slaughter and it was exactly the same in England."
Similarly, when it came down to the definition of a closed herd, Boehringer reports that there was significant lack of understanding about what this actually means.
Matt said: "Of the 62% of English producers that state they are closed herds, 2% rear calves away, 19% bring bulls in, 2% buy in heifers or cows and 1% purchase fattening stock.
"Obviously, this means they are not truly a closed herd and supports previous years when 23% and 24% of ‘closed herd’ producers in 2018 and 2017 respectively also brought bulls onto the farm.
"Add to this that 10% of these herds do not currently vaccinate so will not be protected against the BVD virus, and it is clear to see how vulnerable they are."
In Wales, 56% of herds were classified as closed, yet 12% still brought bulls on to the farm. Likewise in Northern Ireland, 60% of farms classified their herds as closed but 20% brought bulls on to the unit. The vast majority of Scottish herds also claimed to be closed, yet there were still inconsistencies around buying policy and biosecurity.
Matt said: "A certain lack of awareness about both the BVD Stamp it Out initiative and Gwaredu BVD schemes (43% English and 27% of Welsh producers respectively claimed to have no knowledge of these programmes) could actually be a positive for vets. It could be the perfect opportunity to engage in proactive conversations with clients, covering issues such as testing, PI removal and biosecurity."
The new methods, published in Applied and Environmental Microbiology, use a simple swabbing technique to gather samples from the environment which FMD-susceptible animals such as cattle, sheep and pigs commonly make contact with, such as water troughs.
Researchers say the technique requires very little expertise, which makes the sampling method far more accessible, allowing a higher frequency of samples to be collected and processed during an outbreak.
FMD virus is able to survive long periods of time in the environment in the right conditions (up to three months depending on environmental factors such as pH, temperature and relative humidity), so sampling areas where infected animals may have shed virus allows scientists to detect the presence of FMD even if the animals on the farm are no longer showing clinical signs.
The researchers say that novel surveillance techniques such as this can help support a robust response to outbreaks in FMD-free countries, and can also be implemented in endemic areas, such as parts of Asia, Africa and the Middle East, as part of surveillance programs to supplement current information about the spread of FMD.
Dr Claire Colenutt, who led the research at Pirbright said: "Current surveillance methods rely on the recognition of FMD infection in susceptible animals in addition to the collection of samples from the animals which requires veterinary expertise. In keeping the approach simple, samples can be taken by individuals without prior expertise, increasing the number of potential samples, and relieving pressure on veterinary services."
Photo: FMD. Dr. D. Denev
Forte developed the new solution alongside Professor Gayle Hallowell, Professor of Veterinary Internal Medicine and Critical Care at the School of Veterinary Medicine and Science, University of Nottingham.
The company says Hydrafast delivers ideal levels of sodium and glucose. It also contains glycine, an amino acid, acetate, propionate and citrate.
Professor Hallowell said: “This new ORS formula for calves is both practical and research-based, and should address what we know calves need when they have diarrhoea. It provides nutrition as well as an optimal electrolyte balance.”
Hydrafast comes in sachets of 133g. Each box of Hydrafast contains 24 sachets.
Hydrafast is available now from all major veterinary wholesalers, or direct from Forte Healthcare Ltd.
For more information contact your Forte Territory Manager, email enquiries@fortehealthcare.com or visit: www.fortehealthcare.com/product/hydrafast/
Each SoundTalks device has a microphone which covers up to a 10-metre radius.
Noises are transmitted to the cloud where sounds are analysed using algorithms which Boehringer says use many years of data, and with the use of AI are constantly evolving.
The company says the device, which monitors coughing 24/7, has already been shown to detect respiratory disease in pigs up to five days sooner than conventional methods, allowing vets and farmers to respond quicker, improving health outcomes, and minimising the risk of infection across the herd. 1,2
Paul Thompson BA VetMB MRCVS from Garth Pig Practice said: “The earlier we can detect the onset of disease the quicker we can intervene.
"By taking action earlier we can aim to reduce morbidity and mortality, and potentially lessen treatments including antibiotic use.
"This will help improve the wellbeing of the pigs and reduce the time commitments and costs for the farmer.
"Having heard how SoundTalks is already transforming the practices of producers and vets in other parts of Europe, I am excited to use it in my own day-to-day role.
"This innovation has the potential to provide robust data as to when respiratory disease starts, allowing us to refine our prevention plans and improve the overall health of the pigs.”
www.soundtalks.com
Intervet/Schering-Plough Animal Health has announced the launch of Nuflor Minidose - a 50% more concentrated, but less viscous solution of its proven Nuflor antibiotic.
Nuflor Minidose is licensed for the treatment and prevention of bacterial BRD. Intervet/Schering-Plough Animal Health livestock veterinary adviser Rosemary Booth MRCVS said: "It delivers all the rapid efficacy entrusted in Nuflor, but at a lower volume. Whereas a 20ml dose of Nuflor will treat a 150kg animal, the same volume of Nuflor Minidose will cover a 225kg beast. Compared with Nuflor, the new Minidose formulation is easier to administer delivering a less viscous florfenicol solution, with a 62% improvement in viscosity at 15°C and 59% at 5°C."
Rosemary added that Nuflor Minidose is effective against the main bacterial causes of pneumonia: P. multocida, M. haemolytica and H. somni. "Florfenicol is the only antibiotic offering 100% sensitivity to these three key BRD causes in recent trials and its kill effect also ensures that within 24 hours bacteria levels are low enough to prevent any re-growth."
She also pointed out that the new, more concentrated florfenicol solution presents vets with an improved batch treatment option for controlling BRD considering Nuflor is recognised as an effective metaphylactic
"Batch treatment prevents BRD from spreading. Trials with Nuflor have demonstrated the benefit of metaphylactic batch treatment of sick calves in a pen once at least 20% of the animals exhibit disease symptoms. Nuflor was significantly more efficacious than a control in preventing the spread of BRD in healthy calves exposed to infected animals," she explains.
"The bacteria responsible for BRD are found in the respiratory tract of healthy cattle and stress or a greater pathogen load - such as exposure to sick calves - can easily trigger disease. BRD bacterial numbers can double every 30 minutes and in 24 hours, one bacterium can multiply to billions. Batch treatment kills the bacteria before they multiply, release toxins and cause permanent lung damage."
New Nuflor Minidose is licensed for injection subcutaneously for the prevention of BRD at a dose rate of 4ml/45kg and has a 64-day meat withdrawal period.
Centaur has launched a new service on the MyCentaur website which allows for 24-hour ordering from any broadband enabled computer.
A secure practice shopping list with controlled staff access to ordering and management information enables practices to safely control any buying.
According to the company, a key feature of the website is that any orders placed on line by 9pm will be delivered the following day, which gives practices even greater flexibility on ordering times over any existing vet wholesaling ordering service. As well as greater convenience, a financial benefit in using this method of ordering is that all on-line orders attract an additional two per cent discount.
The decision comes after 13 dead wild birds were confirmed to have the virus in Warwickshire.
Last week 17 wild birds were tested positive in Dorset and 31 infected birds have now been identified at the Dorset site. At that time Defra responded by putting a local prevention zone in place and, now it is known the disease is not isolated to the Dorset site, the prevention zone has been extended across the country as a precautionary measure.
The prevention zone means bird keepers across the country must:
Those keepers who have more than 500 birds will need to take extra biosecurity measures that include restricting access to non-essential people, changing clothing and footwear before entering bird enclosures and cleaning and disinfecting vehicles.
The birds in Warwickshire are still being tested but it is expected that it will be the same H5N6 strain of bird flu that was found in the wild birds in Dorset and has been circulating wild birds across Europe. Public Health England have advised the risk to public health is very low with the Food Standards Agency also offering reassurance that bird flu does not pose a food safety risk for UK consumers. Defra has confirmed that the H5N6 strain is different to the strains which affected people in China last year.
Although it does not represent a threat to public, it is highly infectious and deadly to birds.
British Veterinary Association (BVA) President John Fishwick said: "I’d encourage vets to reassure their clients that this strain of Avian Influenza poses a very low risk to public health and the food chain. However, there is clearly a need to try to contain further spread of the disease, which has almost certainly come from migratory birds, and vets and poultry owners should follow the new prevention zone measures and remain vigilant for signs of bird flu."
British Veterinary Poultry Association (BVPA) President Phil Hammond added: "It’s really important that all bird keepers heed biosecurity advice issued by Defra, and maintain the highest biosecurity standards. Any suspicion of Avian Influenza should be reported to the APHA as soon as possible."
Up-to-date advice and guidance on Avian Influenza is available on the Gov.UK website, including how to spot it, what to do if you suspect it, and measures to prevent it:
https://www.gov.uk/guidance/avian-influenza-bird-flu#about-avian-influenza
For further advice on Avian Influenza contact the Defra Helpline on 03459 33 55 77.
Photo: Wild Birds, Shutterstock / aDam Wildlife
MSD Animal Health has obtained regulatory approval in 21 European countries, including the UK, for Cobactan LA 7.5% (cefquinome) - a new-generation, injectable antimicrobial for the treatment of swine respiratory disease (SRD).
Raul Berro DVM, global marketing director swine at MSD Animal Health said: "Cobactan LA 7.5% is a long-acting version of our highly effective Cobactan 2.5%. Its longer duration of action means greater compliance for swine producers with fewer injections and less stress to the animals, without sacrificing performance."
According to the company, the long-acting antibiotic formulation is effective against three major SRD pathogens in growing and finishing pigs - Actinobacillus pleuropneumoniae, Haemophilus parasuis and Pasteurella multocida. Considered the most important threat to the swine industry worldwide, SRD causes increased mortality, decreased weight gain and increased feed consumption.
Cobactan LA 7.5% requires two intramuscular injections 48 hours apart, compared to Cobactan 2.5%, which requires three daily injections. The recommended dose rate is 1 mL (3 mg cefquinome) per 25 kg bodyweight. The product isavailable in 50-ml, 100-ml and 250-ml glass vials.
Raul aded: "COBACTAN LA 7.5% also has a short withdrawal period of seven days. This makes the injectable product also safe to use throughout the finishing period for the treatment of SRD."
MSD adds that the use of COBACTAN LA 7.5% should be according to established responsible use guidelines and strictly according to the label instructions where specific restrictions apply to this class of antibiotics.
For more information, contact your local MSD Animal Health representative or go to www.msd-animal-health.com.
The intranasal vaccine can be administered to calves from one week old. It reduces the clinical signs of respiratory disease and viral shedding from infection with Bovine Respiratory Syncytial Virus (BRSV) and Parainfluenza-3 Virus (Pi3V).
MSD says that no other UK-licensed BRD vaccine can be administered earlier in life, and claims the vaccine delivers the fastest on-farm protection, with an onset of immunity after administration of 5 days for BRSV and 7 days for Pi3V. Duration of immunity is 12 weeks for both viruses.
MSD Animal Health livestock veterinary adviser Dr Kat Baxter-Smith said: "Having this early life calf pneumonia vaccine available in single dose vials will give farmers more practical leeway to be able to vaccinate vulnerable young calves from as young as a week of age, rather than delaying administration until a batch of calves are available. We know that early-age protection of young calves through intranasal vaccination can help prevent pneumonia and positively impact a beef or dairy calf’s productive future".
The new single dose vials are supplied in packs of five, complementing the five dose vials already available.
For further information, contact your MSD account manager.
The new code is one of a series of welfare codes currently being reviewed and updated by the Department for Environment, Food and Rural Affairs (Defra) following recent consultations.
BVA President John Fishwick said: "We warmly welcome these updates and we are particularly pleased to see the vital role the veterinary profession plays in maintaining poultry welfare recognised throughout the new code.
"We are also delighted to see the benefits of veterinary surveillance systems highlighted, with owners and keepers encouraged to use local and national disease surveillance sources to better understand poultry disease patterns and their local health and welfare landscape. This was a key element in our joint consultation response and reflects BVA’s recently published Position on veterinary scanning surveillance (animal health and disease monitoring).
"We are also pleased to see signposting within the Code of Practice to the Humane Slaughter Association’s Code of Practice for the Disposal of Chicks in Hatcheries, which outlines in detail information about humane methods of killing and good practice.
"The British poultry industry has some of the highest welfare standards in the world and the veterinary profession is fully committed to working with Defra on further enhancing animal welfare codes to reflect best industry practice."
Photo: Flock of Chickens (Gallus gallus domesticus) Roaming Freely in Front of Chicken Sheds on a Farm in the Rural Village of Chenson, Devon. Shutterstock / Peter Turner Photography
Sedaxylan 20 mg/ml contains the short acting alpha-2 agonist xylazine and is licensed for I/V administration.
It is also licensed for I/M administration in cattle; it has zero milk withdrawal and short one day meat withdrawal and sedation occurs in cattle within two minutes I/V and five to 10 minutes I/M.
Sedaxylan 20 mg/ml joins Dechra’s Nerfasin vet 100 mg/ml solution in the company’s anaesthesia and sedation range. Nerfasin vet also contains xylazine and is licensed for I/V administration for sedation and premedication prior to general anaesthesia in horses and cattle.
Alana McGlade, national sales manager at Dechra, said: “Dechra offers a comprehensive range of anaesthesia and sedation products allowing vets to customise protocols to the individual animal.
"Sedaxylan 20mg/ml and Nerfasin vet 100 mg/ml solution provide vets with flexible and convenient dosing options.”
Both Sedaxylan 20 mg/ml and Nerfasin vet 100 mg/ml are available in 25ml vials.
For more information, talk to your Dechra territory sales manager.
www.dechra.co.uk.
The Health Products Regulatory Authority (HPRA) has also granted a marketing authorisation in exceptional circumstances (Article 25, 26 EU Reg 2019/6) for Bultavo 3 in Ireland.
The company says that so far, more than 40 million doses of Bultavo 3 have been distributed in Europe to help limit the spread of BTV-3.
Boehringer points to a recent field study published by the German reference laboratory Friedrich-Loeffler-Institut (FLI), which showed that vaccination of sheep and cattle with Bultavo 3 induces immunity against the virus1.
According to the study, animals vaccinated with Bultavo 3 consistently showed evidence of a protective antibody response to BTV-3, although animals vaccinated with other BTV-3 vaccines did not1.
Boehringer says it is now compiling the data needed to obtain a full marketing authorisation in accordance with Article 8 of EU Regulation 2019/6.
The aim of the survey, which closes on 16th June, is to recognise and help raise awareness of the multiple challenges faced by veterinary surgeons undertaking roles for Government as a distinct subset of the veterinary profession.
The Association of Government Veterinarians says that following the survey, it'll be producing a report which identifies issues which affect government vets' wellbeing, identifies existing tools to promote wellbeing within Government and considers developing new ones if necessary. It will also consider best practice and any gaps in the wellbeing services currently available that vets in Government roles would benefit from.
To take part in the survey, visit: https://www.surveymonkey.co.uk/r/vetswellbeing
You can read more about the survey here: https://vets.blog.gov.uk/2018/04/06/how-are-you-feeling-association-of-government-vets-wellbeing-survey-launched/
Photo: Christine Middlemiss introduces the survey.
The ioLight microscope fits in a jacket pocket and the company says it is both simple to use and robust. It unfolds to record and share 5MP still images and real time HD video at a magnification of x200 on an iPad Air. The resolution is 1 micron or 1/1,000 mm, powerful enough to see the structure of plant and animal cells.
The microscope uses standard microscope slides and has adjustable top and bottom illumination for use on both biological and opaque samples.
Iolight says it is particularly good for live samples which deteriorate on the journey back to the lab, and it works anywhere, even without a WiFi or mobile phone network.
Andrew Monk, who founded ioLight with business partner Richard Williams, said: "It takes just a couple of minutes to get a great image on the microscope, anywhere from a river bank to a factory floor. This makes microscopy simpler for everyone, from experienced professionals to student scientists."
The ioLight microscope can be ordered now from www.iolight.co.uk, priced at £840 including VAT.
Zoetis has launched Suvaxyn Parvo/E, a combined vaccine which it says provides the earliest protection of gilts against parvovirus and erysipelas.
Parvovirus and erysipelas infections occur primarily in gilts and sows, negatively impacting their reproductive success and the health of their litters - inevitably reducing profitability.
Nigel Lodge, National Veterinary Manager for Zoetis, said: "The combined vaccine will help ensure the health of gilts and sows is not affected by these two infections which are widespread in the pig herd.
"Suvaxyn® Parvo/E gives the earliest protection so that the ability to vaccinate gilts at five months of age will help ensure a good start to their reproductive life. Up to half of all pigs may be carriers of erysipelas and importantly the vaccine has licensed efficacy against both Erysipelothrix serotypes 1 and 2.
"This brings another vaccine to our portfolio, making it one of the largest in the pig sector and confirming the ongoing commitment of Zoetis to the health and welfare of pigs."
Suvaxyn® Parvo/E is an inactivated combination vaccine approved for immunising gilts and sows to prevent reproductive disorders caused by porcine parvovirus and reduce clinical signs caused by Erysipelothrix rhusiopathiae.
Primary vaccination is recommended from five months of age, with two injections given three to four weeks apart, ensuring the second dose occurs at least four weeks before mating. Revaccination should take place three to four weeks before each subsequent mating.
The vaccine comes in 10-dose and 2 X 25-dose packs. For more information, contact your Zoetis Pig Key Account Manager.
Eurovet Animal Health has launched Marbiflox 10%, a new marbofloxacin preparation for the treatment of respiratory infections in cattle and pigs.
Eurovet says the product can be used flexibly to provide a single dose treatment, with a concentration-dependent effect and a relatively short withdrawal period. Marbiflox can be administered intravenously, subcutaneously or intramuscularly in cattle or intramuscularly in pigs.
The main indications, with reference to good prescribing practice, are for the treatment of respiratory infections caused by sensitive strains of Pasteurella multocida, Mannheimia haemolytica, and Histophilus somni and acute forms of mastitis induced by marbofloxacin-sensitive Escherichia coli strains, during lactation. In pigs the main indication is in the treatment of MMA (metritis mastitis agalactia syndrome).
Further information about Marbiflox and the complete Eurovet range of products is available from Eurovet Animal Health. www.eurovet-ah.co.uk/.
MSD has announced that the broad-spectrum clostridial disease vaccine for sheep and cattle, Bravoxin 10, is now available in a new 6 x 100ml farm vaccination pack. The pack contains enough vaccine for 600 sheep or 300 cattle boosters.
Buyers of the new farm pack will also get a free vaccine applicator worth £20. The new Bravoxin 10 applicator benefits from the sterimatic system, which protects and sterilises the vaccination needle with each injection. MSD says it can also be placed down between doses without risk of needle damage, self-injection or needing to remove the vaccine bottle.
Bravoxin 10 protects both cattle and sheep from clostridial diseases like blackleg and black disease, as well as other conditions caused by clostridial bacteria that usually kill the animal once infection has become established. The vaccine protects against disease caused by the 10 main clostridial bacteria; C. perfringens type A, C.perfringens type B, C.perfringens type C, C.perfringens type D, C.novyi type B, C.septicum, C.tetani, C.sordellii, C.haemolyticum and C.chauvoei.
An impurity was detected during stability monitoring. The impurity was isolated and the best estimate of identity indicated that the impurity is carprofen related.
The problem affects a limited number of batches and is identifiable through quality control testing. The concentration of the process impurity does not increase over time.
This recall is for the following batches only:
Norbrook is contacting wholesale dealers and veterinary surgeons to examine inventory and quarantine products subject to this recall.
For further information regarding the recall, contact Gary Mckee on 0044 2830 264435 or by email: gary.mckee@norbrook.co.uk